United States

Abstract Title: Safety and Efficacy of CB1 Receptor Antagonists for Weight Reduction: A Meta-Analysis

Background: Obesity is a major public health issue that is linked to a variety of comorbidities and increasing healthcare costs. Several pharmacological agents, including cannabinoid type 1 (CB1) receptor antagonists, have been studied for weight management. CB1 receptor antagonists target the endocannabinoid system, which regulate appetite and metabolism, offering potential benefits for weight reduction. However, concerns about psychiatric side effects have limited their clinical use. This meta-analysis aims to evaluate the efficacy and safety of CB1 receptor antagonists in overweight and obese adults to inform the development of safer and more effective therapies.

Methods: We searched PubMed, Embase, CENTRAL, ClinicalTrials.gov, and other sources for randomized controlled trials comparing CB1 receptor antagonists with placebo. Eligible trials enrolled adults with a BMI of 25 kg/m² or higher and reported changes in weight, BMI, waist circumference, fasting glucose, LDL cholesterol, or adverse events. Data were analyzed using RevMan version 5.4, and risk of bias was assessed using the Cochrane RoB 2 tool.

Results: Sixteen randomized controlled trials involving 13,882 participants were included. CB1 receptor antagonists had significantly reduced body weight compared to placebo (MD = −3.05 kg; 95% CI = −3.34 to −2.76; p&lt;0.00001; I² = 17%), and subgroup analysis showed similar effects in short- and long-term follow-up. Waist circumference also had a significant reduction (MD = −2.79 cm; 95% CI = −3.15 to −2.43; p&lt;0.00001; I² = 0%). There was a small but statistically significant decrease in fasting plasma glucose (MD = −0.14 mmol/L; 95% CI = −0.26 to −0.01; p=0.03; I² = 60%), while LDL cholesterol had no change (MD = 0.01 mmol/L; 95% CI = −0.04 to 0.06; p=0.79; I² = 0%). The intervention group experienced a small increase in total adverse events (RR = 1.04; 95% CI = 1.03 to 1.06; p&lt;0.00001; I² = 0%) and a marked increase in psychiatric-related discontinuation (RR = 2.26; 95% CI = 1.69 to 3.03; p&lt;0.00001; I² = 0%). Risk of bias assessment indicated that although some studies were at low risk across all domains, a subset had high risk due to missing outcome data and concerns related to the selection of reported results.

Conclusion: CB1 receptor antagonists demonstrate moderate effectiveness for weight reduction and improvements in waist circumference and glycemic control. However, their clinical utility is limited by dose-dependent psychiatric side effects. Future therapies targeting peripheral CB1 receptors may offer safer alternatives.

2025 AMA Research Challenge – Member Premier Access

Safety and Efficacy of CB1 Receptor Antagonists for Weight Reduction: A Meta-Analysis

Abstract Title: Safety and Efficacy of CB1 Receptor Antagonists for Weight Reduction: A Meta-Analysis

Background: Obesity is a major public health issue that is linked to a variety of comorbidities and increasing healthcare costs. Several pharmacological agents, including cannabinoid type 1 (CB1) receptor antagonists, have been studied for weight management. CB1 receptor antagonists target the endocannabinoid system, which regulate appetite and metabolism, offering potential benefits for weight reduction. However, concerns about psychiatric side effects have limited their clinical use. This meta-analysis aims to evaluate the efficacy and safety of CB1 receptor antagonists in overweight and obese adults to inform the development of safer and more effective therapies.

Methods: We searched PubMed, Embase, CENTRAL, ClinicalTrials.gov, and other sources for randomized controlled trials comparing CB1 receptor antagonists with placebo. Eligible trials enrolled adults with a BMI of 25 kg/m² or higher and reported changes in weight, BMI, waist circumference, fasting glucose, LDL cholesterol, or adverse events. Data were analyzed using RevMan version 5.4, and risk of bias was assessed using the Cochrane RoB 2 tool.

Results: Sixteen randomized controlled trials involving 13,882 participants were included. CB1 receptor antagonists had significantly reduced body weight compared to placebo (MD = −3.05 kg; 95% CI = −3.34 to −2.76; p<0.00001; I² = 17%), and subgroup analysis showed similar effects in short- and long-term follow-up. Waist circumference also had a significant reduction (MD = −2.79 cm; 95% CI = −3.15 to −2.43; p<0.00001; I² = 0%). There was a small but statistically significant decrease in fasting plasma glucose (MD = −0.14 mmol/L; 95% CI = −0.26 to −0.01; p=0.03; I² = 60%), while LDL cholesterol had no change (MD = 0.01 mmol/L; 95% CI = −0.04 to 0.06; p=0.79; I² = 0%). The intervention group experienced a small increase in total adverse events (RR = 1.04; 95% CI = 1.03 to 1.06; p<0.00001; I² = 0%) and a marked increase in psychiatric-related discontinuation (RR = 2.26; 95% CI = 1.69 to 3.03; p<0.00001; I² = 0%). Risk of bias assessment indicated that although some studies were at low risk across all domains, a subset had high risk due to missing outcome data and concerns related to the selection of reported results.

Conclusion: CB1 receptor antagonists demonstrate moderate effectiveness for weight reduction and improvements in waist circumference and glycemic control. However, their clinical utility is limited by dose-dependent psychiatric side effects. Future therapies targeting peripheral CB1 receptors may offer safer alternatives.

Congratulations to all the researchers who have qualified for the AMA Research Challenge virtual poster symposium and semifinals!

Welcome to the **largest national, multi-specialty research event** featuring research from nearly 1,000 medical students, residents, fellows, and international medical graduates across six topic areas - basic science, clinical and translational research, clinical vignettes, health systems science, medical education, and public health and health policy.

#### Access the Event
Use the buttons below or navigation menu to access the event. 

[![](https://assets.underline.io/markdown_image/1/image/d4076f2146939317a29eb9f69c53ad41.png)](https://underline.io/events/506/sessions?searchGroup=all)
[![](https://assets.underline.io/markdown_image/1/image/6bcee0b523a4874c4292ca0415d88dde.png)](https://underline.io/events/506/posters?searchGroup=all)
[![](https://assets.underline.io/markdown_image/1/image/0ca1b933deefd7731529477b45345166.png)](https://underline.io/events/506/schedule)

#### Event Details
The 2025 AMA Research Challenge includes the following symposium halls:
* **Semifinals hall:** Features research from 54 medical students, residents and international medical graduates that received top scores during first round scoring. 
* **Poster symposium hall:** Features research from nearly 1,000 medical students, residents and international medical graduates categorized by topics and subtopics.

**Here’s how to participate:**
* **View posters and presentations** on a variety of topics and specialties
* **Score posters in the semifinals** to help decide the top five finalists (AMA member exclusive opportunity)
* **Connect with presenters** and provide feedback to help advance their research
* **New this year: Watch live poster presentations** by topic area and engage directly with researchers

At the conclusion of this event, the AMA will announce the top five finalists who will advance to the AMA Research Challenge final round, present their research to an elite panel of judges, and compete to win a $10,000 grand prize presented by Laurel Road.

#### A message from Dr. Bobby Mukkamala, AMA President
<div style="position: relative; width: 100%; padding-bottom: 56.25%; height: 0; overflow: hidden;">
  <iframe 
    src="https://underline.io/embed/136894-ama-video?t=0"
    title="AMA Welcome Video"
    allowfullscreen
    style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 0;">
  </iframe>
</div>


#### Recognized Institutions
In 2025, 1,400 abstracts were submitted across six topic areas representing 174 medical schools and more than 150 residency and health care institutions. [See if your institution is represented this year!](https://drive.google.com/file/d/1eFrTqCmCeobx9pr5drJK2hllvsIpFNOY/view?usp=drive_link)

#### Grand Prize Sponsor
AMA would like to thank Laurel Road, a brand of KeyBank, for sponsoring a $10,000 grand prize for the winner of the AMA Research Challenge. Laurel Road and KeyBank are not involved in winner selection process. The winner will be announced during the AMA Research Challenge final round. Payment of the grand prize will be directly from Laurel Road/KeyBank. See the [AMA Research Challenge Official Rules for terms and conditions](https://www.ama-assn.org/system/files/research-challenge-official-rules.pdf).

[![](https://assets.underline.io/uploads/markdown_image/1/image/611e331d4a0eba0920f240cfc04b4d77.png)](https://www.laurelroad.com/)

#### Code of Conduct
<html>
AMA has a code of conduct for its meetings – we ask all attendees to adhere to this code to participate in this year’s meeting. Please read and <a href="https://www.ama-assn.org/about/code-conduct" target="_blank">learn more here</a> about your conduct requirements.
<br><br>
	</html>
	

#### Semifinals Judges

You need to log in with the email address you registered with. Access credentials have been sent to your email. 

Please be sure to check your spam and other email folders if you do not see an email confirmation right away.

Need help? Contact us at <support@underline.io>.

Please log in to explore this event.

If you have used the AMA Research Challenge platform previously, please click the ‘Log-in’ button below. If you do not remember your password, please click “forgot password” and follow prompts to reset your password. After resetting your password, please refresh your webpage to access the platform. 

Register to explore research in a variety of topics. AMA members get exclusive access to score posters in the semifinals. 

**Please use [this link here](https://www.ama-assn.org/member-benefits/events/ama-research-challenge) to register for free. **

Registration Is Required

Join the AMA Research Challenge poster symposium and semifinals to explore top research posters and score posters in the semifinals (an AMA member exclusive opportunity).

Background
Chronic alcohol exposure impairs both the systemic and intestinal immune system. In humans, alcohol use disorder increases sepsis mortality. However, the mechanisms by which alcohol impacts immune dysregulation during sepsis are not well understood. We previously showed that alcohol downregulates the integrin CD103 on regulatory T cells (Tregs), a highly specialized immunosuppressive T cell population, in non-septic mice. We hypothesized that alcohol-induced changes in CD103 signaling on Tregs would increase sepsis mortality. 
Methods
To model chronic alcohol ingestion, B6 mice were randomized to drink either water or alcohol for 12 weeks. At 18-22 weeks, mice underwent cecal-ligation-and-puncture (CLP) to induce polymicrobial intraabdominal sepsis. Mice were sacrificed after 24 hours, and single cell suspensions were prepared from the spleen, lungs, and small intestine for flow cytometric analysis. Comparisons between groups were analyzed using Student’s T Test or Mann Whitney Test. For survival analysis, sex-matched B6 mice underwent CLP. Mice were randomized to receive injections of CD103 blocking antibody or control postoperatively. For Treg depletion, mice received injections of anti-CD25 prior to and at the time of CLP. Mice were followed for seven days, and their survival was compared using Kaplan-Meier curves.
Results
Frequencies of T cell populations in the spleen, lung, and intestine of septic water-fed versus alcohol-fed mice were assessed by flow cytometry. Compared to water-fed mice, alcohol-fed mice had lower frequencies of CD103+Foxp3+CD4+Tregs in the spleen (p=0.0004), lungs (p=0.008), small intestine epithelium (p=0.0004) and lamina propria (p=0.0002). Compared to CD103- Tregs, CD103+ Tregs had higher expression of activation markers (CD44, CD69) and immunosuppressive molecules (CTLA4, PD1, CD39, CD73, TIGI), whereas CD103- Tregs expressed higher levels of a naïve circulating marker (CD62L) and transcription factor associated with the pro-inflammatory Th17 phenotype (RORyt). Tregs from the epithelium of septic alcohol-fed mice expressed higher levels of CD44 (p=0.02) and RORyt (p=0.04) than those from water-fed mice. CD103 blockade significantly increased sepsis mortality in water-fed mice (p=0.03), but did not affect survival in alcohol-fed or Treg-depleted mice. 
Conclusion
Alcohol causes a shift in the Treg population by decreasing the frequency of the highly immunosuppressive CD103+Treg subset during sepsis and a change in Treg phenotype in the small intestine epithelium. CD103 signaling has a protective effect in sepsis. This effect is mediated, in part, by Tregs and eliminated by chronic alcohol exposure. Alcohol-induced downregulation of CD103 on Tregs therefore contributes to immune dysregulation in sepsis.

Effect of Alcohol-Induced Downregulation of Integrin CD103 on Immune Dysregulation in Sepsis

Achondroplasia, the most prevalent skeletal dysplasia, is a genetic disorder caused by activating mutations in the FGFR3 gene impairing endochondral ossification of long bones. Clinical manifestations include disproportionate short stature and multisystem complications. Management has been limited to supportive care, surgical limb lengthening, and recombinant human growth hormone. The latter two carry significant risks and provide modest benefits, respectively. Recently, targeted molecular therapies have emerged as promising alternatives. This review highlights three investigational agents: Vosoritide, Infigratinib, and Naviperigride. Vosoritide, an injectable C-type natriuretic peptide analog, reduces MAPK pathway overactivation; Infigratinib, an oral FGFR1-3 inhibitor, directly suppresses downstream signaling; and Naviperigride, a long-acting CNP prodrug, sustains MAPK inhibition. Clinical trials in children aged 5 years and older demonstrate improved annualized growth velocity compared to baseline: 1.7 cm/year with Vosoritide, 6.0 cm/year with Infigratinib, and 5.4 cm/year with Naviperigride. Safety profiles are favorable with few to no significant treatment-related adverse events reported in the trials reviewed; radius fracture, adenoidal hypertrophy, and sleep apnea were reported for Vosoritide, injection site reactions were reported for Naviperigride, and nasopharyngitis was reported for Infigratinib. Direct comparisons across trials are limited, but available data suggest all three therapies bring growth trajectories of children with achondroplasia closer to unaffected peers. Long-term outcomes, particularly regarding comorbidities such as foramen magnum stenosis, spinal stenosis, and sleep apnea, remain under investigation. These emerging treatments represent a paradigm shift in achondroplasia management, underscoring the need for head-to-head studies and evaluation of combination strategies to optimize efficacy and durability. 


Achondroplasia Treatments in Children Aged 5 and Older

Background
Ewing’s Family of Tumors (EFT) involving the pancreas is exceedingly rare, accounting for only 0.3% of primary pancreatic neoplasms. Due to its nonspecific presentation and limited data, diagnosis and management remain challenging. This systematic review and survival analysis evaluates clinicopathological features, treatment approaches, survival outcomes, and prognostic factors in pancreatic EFT.

Methods
Following PRISMA guidelines, a systematic review (PROSPERO ID CRD42024585711) was conducted across Cochrane Library, Embase, PubMed, and Medline up to August 31, 2024. Case reports, series, and relevant abstracts were included if they provided individual patient data. Data on demographics, clinical features, tumor characteristics, treatment modalities, and survival outcomes were extracted and analyzed using descriptive statistics and Cox proportional-hazards models.

Results
Of 816 screened references, 67 studies (88 patients) were included. The median age was 23 years (IQR: 17-31, range: 2–78), with a slight male predominance (55.1%). The most common symptom was abdominal pain (68.8%). The pancreatic head was the most frequent tumor location (57.0%), with a median tumor size of 8.0 cm (range: 2.1-33.0). 11.4% were secondary tumors, and 22.6% were metastatic at diagnosis. 76.3% were treated with chemotherapy; 52.9% adjuvant and 25.5% neoadjuvant. Regimens used included VDC (Vincristine, doxorubicin, and cyclophosphamide) in 80.6%, IE (Ifosfamide and Etoposide) in 58.1%, and other agents in 19.4%. For local control, surgery (67.9%), radiation (5.1%), or a combination (14.1%) was used. On follow-up, 75.0% remained in remission, 17.6% metastasized, 8.8% recurred locally, and 5.9% progressed despite treatment. Survival outcomes were unavailable for 19 cases; mortality was 42.3% for the remaining, and 43.5% showed no evidence of disease. Patients were followed for a maximum of 120 months (median, 13.75 months). Univariate analysis of overall survival (OS) revealed a hazard ratio (HR) of 0.23 (p=0.02) for primary tumors, 0.36 (p=0.03) for surgically resected tumors without radiation, and 34.29 (p=0.04) for R1 resections. HR for disease-free survival (DFS) was 3.86 (p=0.03) for metastases, 3.38 (p=0.05) for necrotic tumors, and 5.76 (p=0.008) for operatively sampled positive lymph nodes. Age, tumor size, local invasion, and variations in chemotherapy did not produce statistically significant HR for OS or DFS.

Conclusion
Pancreatic ESFT is rare, mostly affecting patients under 30 with a slight male preponderance. The most common symptom is abdominal pain. Complete surgical resection is critical for survival, while necrosis, metastatic disease, and lymph node involvement confer poorer outcomes. Further research is needed to optimize therapeutic strategies.

Survival and Prognosis in Pancreatic Ewing’s Family of Tumors: A Systematic Review

Background
Recently there has been a greater pursuit in the field of orthopaedic research to understand psychological factors and their effect on surgical recovery. Despite the recent expansion in relevant research, we still do not fully understand which risk factors may contribute to the development of depression and anxiety following medial patellofemoral ligament reconstruction (MPFLR) or the impact of these psychological conditions on surgical outcomes. The purpose of this study is to quantify the prevalence of depression and anxiety and its influence prior to and following MPFLR.
Methods
Patients undergoing MPFLR between 12 and 65 years of age were identified using the Truven MarketScan Research Database. Using the International Classification of Diseases, Tenth Revision (ICD-10) codes, patients were screened for a depression or anxiety diagnosis up to three months prior to surgical intervention and up to one year following surgery. Patients were classified as having a preoperative, postoperative, or no depression or anxiety diagnosis. We compared opioid use, reoperation rates, and healthcare utilization costs based on sex and on psychological diagnosis.
Results
A total of 5,109 patients underwent MPFLR between April 2020 and December 2021, of which 3,007 were female (58.9%). Depression or anxiety claims were seen in 1,965 (38.5%) of patients. Preoperatively, 1,071 (35.6%) of females and 313 (14.9%) of males had a new diagnosis of depression or anxiety, and 817 (27.2%) of females and 558 (26.5%) of males used prescribed opioid medications. Postoperatively, 406 (13.5%) of females and 175 (8.3%) of males had a new psychological diagnosis, and 848 (28.2%) of females and 413 (19.6%) of males used opioids at least 60 days following surgery. The overall revision rate was 8.4% (293 females, 137 males). Patients with a new postoperative diagnosis of anxiety or depression had the highest rate of revision MPFL reconstruction (11.2%). During the three-month preoperative phase, the median cost of care for females and males was similar [$1,928 (IQR: $1,020-$3,623) vs. $1,932 ($1,011-$3,436)]. However, during twelve postoperative months, the median cost of healthcare utilization for females was notably larger than for males [$6,822 ($3,498-$13,401) vs. $4,767 ($2,391-$9,886)].
Conclusion
Our data shows that females and patients with depression or anxiety have poorer outcomes following MPFL reconstruction, specifically prolonged opioid use, higher revision rates, and greater healthcare utilization costs. We recommend the addition of targeted psychiatric rehabilitation for these vulnerable cohorts, which may prevent opioid use disorders, promote MPFL healing, and allow greater return to activity.

Prevalence of Depression and Anxiety Following MPFL Reconstruction for Recurrent Patellar Instability

Background
Pelvic incidence (PI) is an anatomical parameter determined by the bony morphology of the pelvis, foundational to determining sagittal spinal alignment. PI has been closely linked to compensatory mechanisms in spinal deformity and overall health-related quality of life. Both excessive and insufficient PI have been associated with adverse outcomes. Prior cross-sectional studies have shown minimal variation in PI during childhood and adolescence. However, our group has identified, through longitudinal analysis, a subset of pediatric patients who experience significant changes in PI over time. This study aimed to investigate the morphological basis for these changes. We hypothesized that changes in PI could result from alterations in the sacral endplate, changes in the orientation or shape of the bony pelvis, or rotation through the sacroiliac (SI) joints.
Methods
We conducted a retrospective study of pediatric patients who demonstrated a change in PI exceeding 6 degrees (in either direction) on lateral spine radiographs obtained at least one year apart. Patients were included only if all relevant bony landmarks were clearly visible on both radiographs. We defined three novel angular measurements to assess pelvic morphology:
• S1-S2 Angle - the angle between the S1 and S2 endplates, used to assess changes in sacral slope. 
• ASIS-PSIS-S1 Angle - the angle between a line connecting the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) and a line extending to the S1 endplate. This angle was designed to evaluate SIJ rotation.
• Hip Angle - the angle formed between the PSIS-ASIS line and a line connecting the PSIS and femoral head center, measuring the vertical position of the hip center. 
Pearson correlation coefficients were calculated for each variable relative to change in PI.
Results
Of 75 patients initially identified, 34 met inclusion criteria. Change in the S1–S2 angle was positively correlated with change in PI (R = 0.56, p < 0.01). Change in hip angle was negatively correlated with PI (R = –0.38, p = 0.03). ASIS–PSIS–S1 angle showed no significant correlation (R = 0.04, p = 0.82).
Conclusion
Morphological measurements reflecting bony growth (sacral slope and hip center position) demonstrated significant correlation with changing PI, supporting the hypothesis that bony development drives PI changes in a subset of pediatric patients. There was no association between PI change and SIJ rotation. These findings underscore the importance of bony growth modulation as a potential future target in managing sagittal alignment during skeletal development.


Characterization of Changing Pelvic Incidence in Pediatric Patients: Identifying the Morphological Changes that Drive Alterations in Pelvic Incidence

Background 
Osteoarthritis is one of the most prevalent musculoskeletal pathologies worldwide, commonly leading to joint degeneration and downstream functional limitations–it is typically reliant on X-ray based imaging for conclusive diagnosis. The advent of AI-based diagnostic imaging for orthopedics and radiology has imparted an interest in the usage of large language models (LLMs) for clinical usage. This study aims to describe the ability of ChatGPT-4o in correctly distinguishing the presence or lack of osteoarthritis on X-ray through binary classification through a publicly available de-identified dataset. 

Methods 
Using images of 500 knees with osteoarthritis and 500 normal knees–made available through a publicly available, de-identified, expert-labeled dataset from Kaggle–images were recursively looped into the ChatGPT-4o API through a standardized prompt to assess its ability in performing binary classification through the statistical metrics of accuracy, sensitivity, specificity, precision, F1-score, recall, and Chi-squared test. Confidence intervals were calculated to establish posterity for future research. 

Results 
ChatGPT-4o demonstrated mixed performance in the binary classification of knee osteoarthritis. 
It demonstrated a low-to-moderate F1-score (0.670, 95% CI 0.699-0.655), precision (0.517, 
95% CI 0.548-0.501), and accuracy (0.532, 95% CI 0.563-0.516). Low specificity (0.114, 95% CI 0.134-0.104) was also noted. High recall (0.950, 95% CI 0.964-0.943) indicated strong performance in positively identifying osteoarthritis images, with an accompanying Chi-squared test (P<0.001) indicating a lack of randomness in performance, clarifying a strong relationship between ChatGPT-4o’s predictions and the ground truth labels. 

Conclusion 
Our mixed results preclude our conclusion that ChatGPT-4o presents with shortcomings in clinical robustness for osteoarthritis diagnosis, and that physicians should, therefore, exercise caution when considering its usage in clinical environments. Further inquiry is required to better understand the capabilities of AI-driven diagnostics for osteoarthritis imaging, requiring the development of large, high-quality, validated datasets. 


Diagnostic Performance of ChatGPT-4o in Identifying Knee Osteoarthritis from X-ray Imaging

Abstract Title:
Medical-Student Led Health Education Workshops for Justice-Involved Populations

Background:
Each year, over 600,000 individuals are released from incarceration in the U.S., many of whom experience high rates of physical and behavioral health conditions. For uninsured individuals, prison or jail may represent their only consistent contact with the healthcare system. Upon reentry, barriers such as low health literacy, housing insecurity, and employment challenges often interfere with chronic disease management. Prior studies suggest that health education interventions can reduce stigma, improve trust in the healthcare system, and enhance post-release engagement. Medical education literature has called for increased exposure to justice-involved populations to deepen student understanding of structural determinants of health. However, a systematic review shows that most medical students receive limited training in this area.

Methods:
To address this gap, we designed a medical student–led health education workshop series at the Middlesex County Juvenile Detention Center in New Jersey. The series covers four core topics: Mental Health, Healthy Relationships, Sexually Transmitted Infections (STIs), and Navigating the Healthcare System; each selected in collaboration with facility staff. Each one-hour, trauma-informed session incorporates videos, interactive activities, and guided discussion. Medical students serve as facilitators, using accessible language and avoiding technical jargon. No identifying information is collected from participants, and the program is framed as a service-learning and educational initiative. 

Results:
As student facilitators, we observed high levels of engagement among participants, including active discussion and thoughtful questions. Contrary to initial assumptions about potential disinterest, students demonstrated enthusiasm and curiosity throughout the sessions. Feedback from both staff and participants guided iterative improvements in communication strategies, emphasizing clarity and contextual understanding. Interactive discussions frequently revealed misconceptions and highlighted the impact of prior life experiences on participants’ perspectives. These insights informed our continued use of a non-assumptive, participant-centered approach.

Conclusion:
This workshop series serves as a dual-impact model to enhance medical student education while addressing health literacy among justice-involved youth. The program fosters early exposure to historically underserved populations, helping to cultivate more empathetic and justice-conscious future providers. We aim to sustain and expand this initiative as a recurring educational experience for both youth and medical students.

The Impact of Medical-Student Led Health Education Workshops for Justice-Involved Populations

Abstract Title
Saving Limbs, Saving Lives: How understanding inpatient diabetes education can change the post-discharge journey

Background
Diabetes is a metabolic condition that affects approximately 11.3% of the United States population (CDC), and approximately 13.2% of the population in Texas specifically (Behavioral Risk Factor Surveillance System (BRFSS)). Worse still, only 50.5% of US adults with diabetes achieve an HbA1c level of less than 7%, indicating poor glycemic control. In summary, the US has a large population that is affected by diabetes, and a significant proportion of that population has uncontrolled disease. One of the major consequences for uncontrolled diabetes is the need for hospitalization and severe complications including lower extremity amputation (LEA), with approximately 82,000 diabetes-related LEA discharges annually. Inpatient diabetes educators play a crucial role in providing patients with self-management education aimed at reducing complications and preventing rehospitalization. Despite its importance, little research exists on the education provided, patient enrollment criteria, and barriers faced by inpatient diabetes educators. Understanding how diabetes education is currently structured in inpatient settings, the challenges educators encounter, and how/if these programs follow up post-discharge is critical to improving educational interventions. With rising diabetes prevalence and frequent hospital readmissions, identifying gaps in inpatient diabetes education is key to improving patient outcomes, decreasing complication burden, and reducing healthcare costs. This research will provide insight to guide future improvements in diabetes education and care transitions. 

Methods
A mixed-methods cross-sectional study will be conducted across four hospital-based diabetes education programs. Diabetes educators completed structured surveys and follow-up interviews assessing criteria for patient inclusion, patient volume, educational content, delivery methods, resource sourcing, validation practices, follow-up protocols, and perceived barriers to education. Survey data will be analyzed using descriptive statistics, and interview transcripts were analyzed thematically.

Results
Our preliminary findings suggest the presence of systemic barriers that hinder access to both inpatient and outpatient diabetes care. Severely ill patients, particularly those hospitalized for diabetes-related complications, often do not receive adequate education or support. Additionally, there appears to be a significant gap in awareness among both patients and providers regarding the availability of free outpatient resources that could substantially benefit this high-risk population.

Conclusion
Findings from this study could inform the development of more consistent, patient-centered, and scalable diabetes education resources. Furthermore, it could more efficiently spread knowledge of existing and underutilized outpatient resources available to vulnerable populations. These insights may guide institutional policy, funding decisions, and future research aimed at improving chronic disease education across diverse healthcare settings.

Saving Limbs, Saving Lives: How understanding inpatient diabetes education can change the post-discharge journey

Abstract Title
PAC Participation in Urology: Identifying Gaps and Opportunities for Growth

Background
Political advocacy allows physicians to influence healthcare policy and protect their profession. While the American Urological Association (AUA) Political Action Committee (PAC) supports urology-specific issues such as reimbursement, workforce development, and scope of practice, engagement among urologists remains limited. Understanding demographic and regional trends may help guide future outreach and infrastructure.

Methods
We conducted a cross-sectional analysis of 2023 and 2024 AUA PAC contributor data, integrating AUA Census information to evaluate trends by region, gender, and estimated age (approximated as residency completion year plus 35). Participation rates were calculated across demographic subgroups.

Results
National AUA PAC participation increased slightly from 1.09% in 2023 to 1.23% in 2024. New York had the highest engagement at 2.72%, while all other regions remained below 2%. Urologists aged 35 years or younger had the highest age-based participation in 2024 at 5.44%. Female urologist participation increased from 1.56% in 2023 to 2.86% in 2024. Women contributed at higher proportional rates than men in several regions in 2023, and in all eight AUA regions in 2024, making them the most engaged demographic group proportionally.

Conclusion
Although overall AUA PAC engagement remains low, rising participation among younger and female urologists represents a promising shift. These groups are leading advocacy efforts proportionally and may hold the key to expanding urology’s political influence. Building targeted mentorship and outreach strategies to support and scale this trend can help align urology with broader national advocacy standards, such as those championed by the AMA.





PAC Participation in Urology: Identifying Gaps and Opportunities for Growth

Background: Testosterone deficiency in men is often framed as a biological or age-related condition, yet hormone levels may also reflect broader social determinants of health (SoDH) and masculinity-related stressors. As a hormone tied to male identity, testosterone may operate as both a physiological signal and a social barometer. This study applied the Healthy People 2030 SoDH framework, integrating economic stability, education, healthcare access, neighborhood environment, and social context with biological and behavioral factors, to examine predictors of testosterone deficiency in U.S. men.
Methods: We analyzed data from four NHANES cycles (2011–2016, 2021–2023), including 10,357 men aged ≥18 years with valid total testosterone measurements. Men reporting exogenous testosterone prescriptions (n = 41) were excluded. Testosterone deficiency was defined as total serum testosterone <300 ng/dL. Predictor variables included BMI, fasting glucose, sedentary time, sleep duration, depressive symptoms (PHQ-2 ≥3), smoking, income-to-poverty ratio, employment, education, health insurance, usual source of care, housing size, marital status, and race/ethnicity. Multivariable logistic regression models adjusted for age and NHANES survey design. All analyses were performed in R version 4.5.0
Results: The prevalence of testosterone deficiency was 25.7%, declining from 28.1% in 2011–2012 to 20.3% in 2021–2023 (p-trend <0.01). Obesity (BMI ≥30) (AOR = 2.69, 95% CI [2.36–3.06], p <0.001), impaired fasting glucose (100–125 mg/dL) (AOR = 1.55, 95% CI [1.27–1.90], p <0.001), diabetes-range glucose (≥126 mg/dL) (AOR = 2.92, 95% CI [2.03–4.21], p <0.001), and prolonged sedentary behavior (≥8 h/day) (AOR = 1.39, 95% CI [1.14–1.70], p <0.01) were independently associated with greater odds of deficiency. Men without a usual source of care had higher odds (AOR = 1.27, 95% CI [1.05–1.54], p <0.05). Current smoking was associated with lower odds (AOR = 0.79, 95% CI [0.65–0.97], p <0.05). In the social context domain, never-married men had significantly lower odds compared with married men (AOR = 0.70, 95% CI [0.57–0.86], p <0.001). Race/ethnicity, education, income, and employment were not significant predictors.
Conclusion: Testosterone deficiency in U.S. men is strongly shaped by metabolic and behavioral risk factors, but also by relational status and healthcare access. These findings support reframing testosterone as a biopsychosocial marker that reflects not only physiology but also the ways men inhabit social roles, relationships, and expectations of masculinity. Addressing men’s hormonal health may therefore require integrating medical care with broader attention to gendered norms, social stressors, and cultural context.

Next from 2025 AMA Research Challenge – Member Premier Access

Effect of Alcohol-Induced Downregulation of Integrin CD103 on Immune Dysregulation in Sepsis